Lots More on What's Hot at JPM's Health Conference

Episode Summary

Executive Summary: The episode centers on James Van Geelen’s takeaways from the JPMorgan Healthcare Conference, where GLP-1 drugs and AI-driven drug discovery dominated conversation. The discussion highlights continued optimism around Eli Lilly and Novo Nordisk, the emerging importance of oral GLP-1s, the potential for combination therapies that preserve muscle, and how AI is reshaping biotech R&D by helping companies fail faster and spend more efficiently.

Main Topics: GLP-1 drugs remain the conference’s dominant theme (Priority: 5/5): Attendees are still focused on weight-loss drugs, especially Eli Lilly and Novo Nordisk, whose stocks keep hitting highs amid expanding research into new uses beyond obesity. Oral GLP-1 formulations as the key supply breakthrough (Priority: 5/5): The conversation emphasizes that oral versions may matter less for convenience than for overcoming manufacturing and supply constraints associated with auto-injectors. Combination therapies to preserve or build muscle (Priority: 5/5): A second major GLP-1 theme is pairing these drugs with treatments that reduce muscle loss or even increase lean mass, making obesity treatment more effective and potentially safer for older patients. AI and ‘drug GPT’ in biotech (Priority: 4/5): AI was heavily featured at the conference, with examples from Recursion, Sanofi, Amgen, and Nvidia, reflecting the industry’s push toward predictive drug discovery and faster failure in R&D. Funding conditions and interest rates matter for biotech (Priority: 4/5): Lower or stabilizing rates are seen as a relief after a difficult period for biopharma and biotech funding, especially after regional bank stress and Silicon Valley Bank’s collapse. Winners, losers, and second-order trades (Priority: 3/5): The speakers note that investors often chase secondary beneficiaries of major trends, but the market has largely concentrated gains in the clear winners like Lilly, Novo, and Nvidia while other names have lagged. Conference atmosphere and networking dynamics (Priority: 2/5): The episode also paints a picture of the conference environment itself—tight security, crowded networking, and intense interest in prominent speakers and companies.

Key Arguments: GLP-1 demand is still massive and not close to saturated; supply remains the main bottleneck rather than lack of patient interest. Oral GLP-1s could be transformative because pills are easier to manufacture at scale than auto-injectors, potentially unlocking more of the addressable market. The real opportunity in GLP-1s may be combination drugs that preserve or build muscle while patients lose fat, improving both health and aesthetics. AI drug-discovery tools may not instantly cure disease, but they can make biotech R&D more efficient by screening out dead ends earlier. Much of biotech’s recent optimism is tied to a better funding backdrop and the possibility of lower rates after a painful tightening cycle. Market reactions have already priced in some of GLP-1’s negative effects on adjacent industries, so some of the feared damage may be less severe than initially expected. Investors should be cautious about chasing second- and third-order trades; value has concentrated in the main platform winners rather than the obvious adjacent plays.

Data Points: Episode format: 5 minutes or less - Bloomberg’s Stock Movers promo describes the new report format Conference date referenced: January 10 - The hosts note the recording date while discussing market highs Novo Nordisk stock: Yet another all-time high - Referenced as still surging on the day of recording Eli Lilly/Novo at highs since prior episode: 81% of the time at all-time highs - James says he checked the stocks after a previous appearance GLP-1 user count in the U.S.: 500,000 people - Current approximate number of users mentioned as a baseline Potential U.S. addressable market: 110 million people - James says this is the theoretical pool of people who could or should take GLP-1 drugs Versanus acquisition price: $4 billion - Regeneron bought Versanus, which has a combo drug discussed in the segment Body weight loss in phase 1 trial: 12% - Migromab combined with semaglutide or another GLP-1 drug Lean muscle mass change in phase 1 trial: 6% increase - Reported for the combination therapy in the phase 1 data Pfizer stock comparison: Same level as 10 years ago / since 2014 - Used to illustrate how missing GLP-1 participation may have hurt performance Drug discovery presentation time: 7:15 in the morning - Recursion’s presentation was early and sparsely attended Conference ratio described: 90 men and two women - Used to characterize the gender imbalance in the networking crowd

Pivotal Quotes: "the oral drug will make it so that they can take advantage of this huge demand" — James Van Geelen: Explaining why oral GLP-1s matter more as a supply solution than a convenience feature "they spend so much time and money on things that might just not work" — James Van Geelen: Describing why AI could be valuable in drug development by helping companies fail faster "If you have a program that can basically make you faster to fail, right, where you're kind of figuring out what's going to be a waste of time and what might not be more effectively that that's huge" — James Van Geelen: Summarizing the potential productivity gain from AI-assisted biotech R&D

Implications: Healthcare investors should watch GLP-1 supply, oral formulations, and combo therapies as the next major catalysts. AI is becoming a real biotech tool, not just hype. The biggest gains may stay concentrated in platform leaders, while adjacent “winners” are riskier bets.